Although new U.S. tariffs on Canada, Mexico, and China are putting pressure on markets, investors are shifting toward ...

Around the same time, the prototype of the Squibb logo was designed ... by 1929, turned Bristol-Myers into a publicly held company on the New York Stock Exchange. The post World War 1 depression ...

we estimate Bristol Myers Squibb’s valuation to be around $61 per share, aligning closely with the current market price. While new drug approvals offer potential upside, the immediate financial ...

Sandra Leung, one of the longest-serving legal chiefs in the pharmaceutical industry, plans to retire from Bristol Myers Squibb in 2025 ... The Princeton, New Jersey-based company whose ...

I will point out why Bristol-Myers Squibb's share price still does not reflect the success in commercializing its drugs. Even though the Princeton, New Jersey-based company was able to beat the ...

Bristol Myers (BMY) Squibb announced new five-year results from the POETYK PSO long-term extension trial of Sotyktu treatment in adult patients with moderate-to-severe plaque psoriasis.

Bristol Myers (BMY) Squibb announced new five-year results from the POETYK PSO long-term extension, LTE, trial of Sotyktu treatment in adult patients with moderate-to-severe plaque psoriasis.

Bristol-Myers Squibb Company (NYSE:BMY) remains focused on advancing new molecular entities while also pursuing strategic acquisitions to bolster its research and development capabilities.